Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Journal of Diabetes Science and Technology|February 11, 2010
Oral insulin: the rationale for this approach and current developmentsEhud Arbit, Miriam KidronJournal of Diabetes Science and Technology|June 28, 2017
Oral Insulin Delivery in a Physiologic Context: ReviewEhud Arbit, Miriam KidronPlos One|April 18, 2013
Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot studyRoy Eldor, Ehud Arbit, Asher Corcos, et al.Clinical Therapeutics|December 7, 2005
Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover studySimona Cernea, Miriam Kidron, Jay Wohlgelernter, et al.Diabetes, Obesity & Metabolism|July 26, 2021
Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: A randomized, placebo-controlled trialRoy Eldor, Joel Neutel, Kenneth Homer, et al.Journal of Diabetes Science and Technology|December 7, 2010
Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine modelsRoy Eldor, Miriam Kidron, Yael Greenberg-Shushlav, et al.Clinical Therapeutics|April 13, 2005
Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp techniqueSimona Cernea, Miriam Kidron, Jay Wohlgelernter, et al.Diabetes Care|May 28, 2005
Dose-response relationship of oral insulin spray in healthy subjectsSimona Cernea, Miriam Kidron, Jay Wohlgelernter, et al.Diabetes, Obesity & Metabolism|October 25, 2022
Oral insulin (ORMD-0801) in type 2 diabetes mellitus: A dose-finding 12-week randomized placebo-controlled studyRoy Eldor, Bruce H Francis, Alexander Fleming, et al.Gastro Hep Advances|August 12, 2024
Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical TrialYuval Ishay, Joel Neutel, Yotam Kolben, et al.Pageof 1